Abstract
Theoretical assumptions about how psychotropic drugs ‘work’ are rarely discussed explicitly. In a ‘disease-centred model,’ drugs are believed to work by acting on a disease process. In contrast, in a ‘drug-centred model,’ the characteristic physiological, behavioural and subjective effects of drugs are used to define drug action. The therapeutic value of a drug stems from the usefulness of these effects in clinical situations. The disease-centred model appears dominant but has weaknesses: (1) it cannot logically justify the use of drugs since major pathophysiological hypotheses were derived from selectively observed actions of drugs; (2) comparisons between drugs believed to have specific effects in certain conditions and drugs thought to have non-specific effects fail to support it; (3) outcome measures for various disorders include items responsive to non-specific drug effects; (4) studies with healthy volunteers describe characteristic drug-induced states independently of a psychiatric diagnosis; (5) animal tests show effects with agents not usually thought of as specific treatments for the conditions modelled by tests. This article offers suggestions to develop a drug-centred model and discusses its potential impact on clinical practice.
References
1.
Royal College of Psychiatrists: Antidepressants facts sheet. London, Royal College of Psychiatrists, 2002.
2.
Valenstein E: Blaming the brain: The truth about drugs and mental health. New York, Harper, 1998.
3.
Kapur S: Psychosis as a state of aberrant salience: A framework linking biology, phenomenology and pharmacology in schizophrenia. Am J Psychiatry 2003;160:13–23.
4.
Rang HP, Dale MM, Ritter JM: Pharmacology, ed 5. Edinburgh, Churchill Livingstone, 2003.
5.
Hyman SE, Nestler EJ: Initiation and adaptation: A paradigm for understanding psychotropic drug action. Am J Psychiatry 1996;153:151–162.
6.
Hyman SE, Nestler EJ: Drs Hyman & Nestler reply. Am J Psychiatry 1997;154:440–441.
7.
Breggin PR: Brain disabling treatments in psychiatry: Drugs, electroshock, and the role of the FDA. New York, Springer, 1997.
8.
Healy D: The antidepressant era. New York, Harvard University Press, 1999.
9.
Healy D: The creation of psychopharmacology. New York, Harvard University Press, 2002.
10.
Kaiser D: Against biological psychiatry. Psychiatric Times 1996;12. URL: http://www.psychiatrictimes.com/p961242.html.
11.
Ross CA, Pam A: Pseudoscience in biological psychiatry: Blaming the body. New York, Wiley, 1995.
12.
Sullivan HS: Schizophrenia as a human process. New York, Norton, 1962.
13.
Lehmann H: The introduction of chlorpromazine to North America. Psychiatr J Univ Ott 1989;14:263–265.
14.
Deniker P: Experimental neurological syndromes and the new drug therapies in psychiatry. Compr Psychiatry 1961;1:92–100.
15.
Malitz S, Hoch PH, Lesse S: A two-year evaluation of chlorpromazine in clinical research and practice. Am J Psychiatry 1956;113:540–548.
16.
Winkelman NW Jr: An appraisal of chlorpromazine: General principles for administration of chlorpromazine based on experience of 1090 patients. Am J Psychiatry 1957;114:161–168.
17.
Sargant W, Slater E: An introduction to physical methods of treatment in psychiatry. Edinburgh, Livingstone, 1944.
18.
Mayer-Gross W, Slater E, Roth M: Clinical psychiatry, ed 1. London, Cassel & Co, 1954.
19.
Moncrieff J: An investigation into the precedents of modern drug treatment in psychiatry. Hist Psychiatry 1999;10:475–490.
20.
Gelman S: Medicating schizophrenia: A history. New Brunswick, Rutgers University Press, 1999.
21.
Shorter E: A history of psychiatry: From the age of the asylum to the age of Prozac. New York, Wiley, 1997.
22.
Klerman GL: The evolution of a scientific nosology; in Shershow JC (ed): Schizophrenia: Theory and Practice. Cambridge, Harvard University Press, 1978.
23.
Van Rossum JM: The significance of dopamine blockade for the mechanism of action of neuroleptic drugs. Arch Int Pharmacodyn Ther 1966;160:492–494.
24.
Salzman C, Miyawaki EK, le Bars P, Kerrihard TN: Neurobiologic basis of anxiety and its treatment. Harv Rev Psychiatry 1993;1:197–206.
25.
Suranyi-Cadotte BE, Bodnoff SR, Welner SA: Antidepressant-anxiolytic interactions: Involvement of the benzodiazepine-GABA and serotonin systems. Prog Neuropsychopharmacol Biol Psychiatry 1990;14:633–654.
26.
Soares JC, Innis RB: Neurochemical brain imaging investigations of schizophrenia. Biol Psychiatry 1999;46:600–615.
27.
Khan AU: How do psychotropic medications really work? Psychiatr Times 1999;16 (10). URL: http://www.mhsource.com/edu/psytimes/p991012.html.
28.
Casey JF, Bennett IF, Lindley CJ, Hollister LE, Gordon MH, Springer NN: Drug therapy in schizophrenia. Arch Gen Psychiatry 1960;2:210–220.
29.
Casey JF, Lasky JL, Klett CJ, Hollister LE: Treatment of schizophrenia reactions with phenothiazine derivatives. Am J Psychiatry 1960;117:97–105.
30.
Abse DW, Dahlstrom WG, Tolley AG: Evaluation of tranquilising drugs in the management of acute mental disturbance. Am J Psychiatry 1960;116:973–980.
31.
Wolkowitz OM, Pickar D: Benzodiazepines in the treatment of schizophrenia. Am J Psychiatry 1991;148:714–726.
32.
Carpenter WT, Buchanan RW, Kirkpatrick B, Breier AF: Diazepam treatment of early signs of exacerbation in schizophrenia. Am J Psychiatry 1999;156:299–303.
33.
Moncrieff J: Are antidepressants over-rated? A review of methodological problems with antidepressant trials. J Nerv Ment Dis 2001;189:288–295.
34.
Robertson MM, Trimble MR: Major tranquilisers used as antidepressants. A review. J Affect Dis 1982;4:173–193.
35.
Greenberg RP, Fisher S: Suspended judgement. Seeing through the double masked design: A commentary. Control Clin Trials 1994;15:244–246.
36.
Prien RF, Caffey EM, Klett CJ: Comparison of lithium carbonate and chlorpromazine in the treatment of mania. Arch Gen Psychiatry 1972;26:146–153.
37.
Garfinkel PE, Stancer HC, Persad E: A comparison of haloperidol, lithium carbonate and their combination in the treatment of mania. J Affect Dis 1980;2:279–288.
38.
Braden W, Fink EB, Qualls CB, Ho CK, Samuels WO: Lithium and chlorpromazine in psychotic inpatients. Psychiatr Res 1982;7:69–81.
39.
Johnstone EC, Crow TJ, Frith CD, Owens DG: The Northwick Park ‘functional’ psychosis study: Diagnosis and treatment response. Lancet 1988;ii:119–125.
40.
Moncrieff J: Lithium revisited. A re-examination of the placebo-controlled trials of lithium prophylaxis in manic-depressive disorder. Br J Psychiatry1995;167:569–573.
41.
Goodwin GM: Recurrence of mania after lithium withdrawal. Br J Psychiatry 1994;164:149–152.
42.
Perlis RH, Sachs GS, Lafer B, Otto MW, Faraone SV, Kane JM, Rosenbaum JF: Effect of abrupt change from standard to low serum levels of lithium: Reanalysis of double-blind lithium maintenance data. Am J Psychiatry 2002;159:1155–1159.
43.
Davis JM, Janicak PG, Hogan DM: Mood stabilisers in the prevention of recurrent affective disorders: A meta-analysis. Acta Psychiatr Scand 1999;100:406–417.
44.
Cavanagh J, Smyth R, Goodwin GM: Relapse into mania or depression following lithium discontinuation: A 7-year follow-up. Acta Psychiatr Scand 2004;109:91–95.
45.
Ramaekers JG, Louwerens JW, Muntjewerff ND, Milius H, de Bie A, Rosenzweig P, et al: Psychomotor, cognitive, extrapyramidal, and affective functions of healthy volunteers during treatment with an atypical (amisulpiride) and a classic (haloperidol) antipsychotic. J Clin Psychopharmacol 1999;19:209–221.
46.
McClelland GR, Cooper SM, Pilgrim AJ: A comparison of the central nervous system effects of haloperidol, chlorpromazine and sulpiride in normal volunteers. Br J Clin Pharmacol 1990;30:795–803.
47.
Rammsayer T, Gallhofer B: Remoxipride versus haloperidol in healthy volunteers: Psychometric performance and subjective tolerance profiles. Int Clin Psychopharmacol 1995;10:31–37.
48.
Healy D, Farquhar G: Immediate effects of droperidol. Hum Psychopharmacol 1998;13:113–120.
49.
Cohen D: A critique of the use of neuroleptic drugs in psychiatry; in Fisher S, Greenberg RG (eds): From placebo to panacea. New York, Wiley, 1997, pp 173–229.
50.
Kropf D, Muller-Oerlinghausen B: Changes in learning, memory, and mood during lithium treatment. Approach to a research strategy. Acta Psychiatr Scand 1979;59:97–124.
51.
Judd LL, Hubbard B, Janowsky DS, Huey LY, Attewell PA: The effect of lithium carbonate on affect, mood, and personality of normal subjects. Arch Gen Psychiatry 1977;34:46–51.
52.
Muller-Oerlinghausen B, Hamann S, Herrmann WM, Kropf D: Effects of lithium on vigilance, psychomotoric performance and mood. Pharmakopsychiatr Neuropsychopharmakol 1979;12:388–396.
53.
Tranter R, Healy H, Cattell D, Healy D: Functional effects of agents differentially selective to noradrenergic or serotonergic systems. Psychol Med 2002;32:517–524.
54.
Hermann WM, McDonald RJ: A multidimensional test approach for the description of the CNS activity of drugs in human pharmacology. Pharmakopsychiatr Neuropsychopharmakol 1978;11:247–265.
55.
Kirsch I, Moore TJ, Scoboria A, Nicholls SS: The emperor’s new drugs: An analysis of antidepressant medication data submitted to the U.S. Food and Drug Administration. Prev Treat 2002;5(article 23). URL: http://www.journals.apa.org/prevention/volume5/pre005 0023a.html.
56.
Willner P: Behavioural models in psychopharmacology; in Willner P (ed): Behavioural models in psychopharmacology: Theoretical, industrial and clinical perspectives. Cambridge, Cambridge University Press, 1991, pp 3–18.
57.
Weiss JM, Kilts CD: Animal models of depression and schizophrenia; in Schatzberg AF, Nemeroff CB (eds): The American Psychiatric Press Textbook of Psychopharmacology, ed 2. Washington, American Psychiatric Press, 1998, pp 89–132.
58.
Bourin M, Fiocco AJ, Clenet F: How valuable are animal models in defining antidepressant activity? Hum Psychopharmacol Clin Exp 2001;16:9–21.
59.
Parra A: A common role for psychotropic medications: Memory impairment. Med Hyp 2003;60:133–142.
60.
Cryan JF, Markou A, Lucki I: Assessing antidepressant activity in rodents: Recent developments and future needs. Trend Pharmacol Sci 2002;23:238–245.
61.
Jacobs D, Cohen D: What is really known about psychological alterations produced by psychiatric drugs? Int J Risk Safety Med 1999;12:37–47.
62.
Fava GA, Ruini C, Rafanelli C: Psychometric theory is an obstacle to the progress of clinical research. Psychother Psychosom 2004;73:145–148.
63.
Fava M, Evans AE, Dorer DJ, Schoenfeld DA: The problem of the placebo response in clinical trials for psychiatrc disorders: Culprits, possible remedies and a novel study design approach. Psychother Psychosom 2003;72:115–127.
64.
Demyttenaere K, De Fruyt J: Getting what you ask for: On the selectivity of depression rating scales. Psychother Psychosom 2003;72:61–70.
65.
Bzechlybnik-Butler K, Jeffries JJ: Clinical handbook of psychotropic drugs, ed 12, revised. Seattle, Hogrefe & Huber, 2002.
66.
Paton C, Banham S, Whitmore J: Benzodiazepines in schizophrenia. Is there a trend towards long-term prescribing? Psychiatr Bull 2000;24:113–115.
67.
Cohen D, McCubbin M, Collin J, Perodeau G: Medications as social phenomena. Health 2001;5:61–77.
68.
Cohen D: The psychiatric medication history: Context, meaning, and purpose. Soc Work Ment Health 2003;1:5–28.
© 2005 S. Karger AG, Basel
2005
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
